Resource Summary Report

Generated by kravitz2 on Aug 16, 2026

APC anti-human CD14

RRID:AB_830681
Type: Antibody

Proper Citation

BioLegend Cat# 325608, RRID:AB_830681

Antibody Information

URL: http://antibodyregistry.org/AB_830681

Proper Citation: BioLegend Cat# 325608, RRID:AB_830681

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD14

Description: This monoclonal targets CD14

Target Organism: human

Clone ID: Clone HCD14

Antibody ID: AB_830681

Vendor: BioLegend

Catalog Number: 325608

Alternative Catalog Numbers: 325607

Record Creation Time: 20250819T225823+0000

Record Last Update: 20250820T035317+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD14.

No alerts have been found for APC anti-human CD14.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at kravitz2 .

Ghoochani A, et al. (2026) Cell-type resolved protein atlas of brain lysosomes identifies SLC45A1-associated disease as a lysosomal disorder. Cell, 189(3), 765.

Martin A, et al. (2025) IFN-?? licenses normal and pathogenic ALPK1/TIFA pathway in human monocytes. iScience, 28(1), 111563.

Fang Y, et al. (2025) Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. STAR protocols, 6(2), 103810.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med (New York, N.Y.), 100804.

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. STAR protocols, 6(2), 103742.

Zhang P, et al. (2025) Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies. Cancer discovery.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience, 26(10), 107952.

Sikder MAA, et al. (2023) Maternal diet modulates the infant microbiome and intestinal Flt3L necessary for dendritic cell development and immunity to respiratory infection. Immunity, 56(5), 1098.

Li YR, et al. (2022) Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. iScience, 25(9), 104859.

Li YR, et al. (2021) Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell reports. Medicine, 2(11), 100449.

Wang E, et al. (2021) Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation. Cell stem cell, 28(4), 718.

Hearnden R, et al. (2021) Isolation of stromal vascular fraction cell suspensions from mouse and human adipose tissues for downstream applications. STAR protocols, 2(2), 100422.

Zhou Y, et al. (2021) Methods for Studying Mouse and Human Invariant Natural Killer T Cells. Methods in molecular biology (Clifton, N.J.), 2388, 35.

Zhu Y, et al. (2019) Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell stem cell, 25(4), 542.